{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-025203","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.792214+00:00","generated_at":"2026-06-10T23:51:42.211645+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CMO Kirsten Gruis resigns; interim CMO Jordan Dubow appointed for stroke trial","bullets":["CMO Kirsten Gruis resigned effective Aug 31, 2023; she will consult for 9 months at $33,500/month.","Jordan Dubow, M.D., vascular neurologist with extensive CMO experience, engaged as interim CMO.","Dr. Dubow to accelerate site engagement and enrollment in Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke.","Dr. Dubow has served as CMO for eight companies and worked on 16 NDAs through FDA's Division of Neurology.","Separation agreement includes standard non-disparagement and confidentiality; no severance as resignation was voluntary."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-025203","json":"https://secwatch.observer/filing/0001437749-23-025203.json","markdown":"https://secwatch.observer/filing/0001437749-23-025203.md","text":"https://secwatch.observer/filing/0001437749-23-025203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/0001437749-23-025203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/dmtp20230903_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:51:42.211645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0462421809","claim":"Kirsten Gruis resigned as Chief Medical Officer at DiaMedica Therapeutics Inc..","evidence_excerpt":"On September 3, 2023, Kirsten Gruis, M.D. resigned from her position as Chief Medical Officer of DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”), effective as of August 31, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/0001437749-23-025203-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"f5c4ceedc4","claim":"Jordan Dubow was appointed as Chief Medical Officer at DiaMedica Therapeutics Inc..","evidence_excerpt":"To replace Dr. Gruis immediately on an interim basis while DiaMedica completes its search for a permanent Chief Medical Officer, DiaMedica has engaged as an independent consultant, Jordan Dubow, M.D.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/0001437749-23-025203-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"engaged"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}